Found: 11
Select item for more details and to access through your institution.
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-00449-z
- By:
- Publication type:
- Article
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
- Published in:
- Oncologist, 2024, v. 29, n. 1, p. 25, doi. 10.1093/oncolo/oyad201
- By:
- Publication type:
- Article
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1223282
- By:
- Publication type:
- Article
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin.
- Published in:
- Carcinogenesis, 2013, v. 34, n. 9, p. 2137, doi. 10.1093/carcin/bgt155
- By:
- Publication type:
- Article
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
- Published in:
- Journal of Gynecologic Oncology, 2024, v. 35, n. 2, p. 1, doi. 10.3802/jgo.2024.35.e40
- By:
- Publication type:
- Article
Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica.
- Published in:
- Pharmacy Practice (1886-3655), 2018, v. 16, n. 4, p. 1, doi. 10.18549/PharmPract.2018.04.1214
- By:
- Publication type:
- Article
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 4, p. 1101, doi. 10.1007/s00262-020-02748-9
- By:
- Publication type:
- Article
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 6, p. 1241, doi. 10.1002/ijc.34608
- By:
- Publication type:
- Article
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1343027
- By:
- Publication type:
- Article
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1223282
- By:
- Publication type:
- Article